Picture1.png
Acumen Pharmaceuticals Announces Pricing of Upsized Initial Public Offering
June 30, 2021 22:44 ET | Acumen Pharmaceuticals, Inc.
CHARLOTTESVILLE, Va., June 30, 2021 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (“Acumen” or “Acumen Pharmaceuticals”) (Nasdaq: ABOS), a clinical-stage biopharmaceutical company developing a...
Vaccinex logo
CORRECTION -- Vaccinex to Present Additional SIGNAL Data at Huntington Study Group 2020 Medical Conference
October 29, 2020 11:15 ET | Vaccinex, Inc.
SIGNAL Phase 2 trial data continue to support cognitive benefit and reduced brain atrophy with pepinemab treatment in Huntington’s disease Data provide strong rationale for continued development in...
Vaccinex logo
Vaccinex to Present Additional SIGNAL Data at Huntington Study Group 2020 Medical Conference
October 29, 2020 07:55 ET | Vaccinex, Inc.
SIGNAL Phase 2 trial data continue to support cognitive benefit and reduced brain atrophy with pepinemab treatment in Huntington’s disease Data provide strong rationale for continued development...
Vaccinex logo
Vaccinex, Inc. to Present at the Virtual Investor KOL Roundtable
October 26, 2020 07:55 ET | Vaccinex, Inc.
ROCHESTER, N.Y., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative...
Vaccinex logo
Top-Line Results of Phase 2 SIGNAL Study in Huntington’s Disease Support Potential for Cognitive Benefit of Pepinemab
September 22, 2020 07:30 ET | Vaccinex, Inc.
Key cognitive endpoints trending towards but did not reach statistical significance in early manifest population. Overall study does not meet pre-specified co-primary endpoints Results support...
Vaccinex logo
Vaccinex Provides Update of Potentially Pivotal SIGNAL Clinical Trial in Huntington’s Disease
July 07, 2020 07:55 ET | Vaccinex, Inc.
ROCHESTER, N.Y., July 07, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in Huntington’s disease...
Vaccinex logo
Vaccinex Delivers Virtual Presentation at the Advances in Alzheimer’s and Parkinson’s Therapies AAT-AD/PD™ Focus Meeting 2020
April 07, 2020 07:55 ET | Vaccinex, Inc.
ROCHESTER, N.Y., April 07, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and...
Vaccinex logo
Vaccinex Announces $3 Million Award from the Alzheimer’s Drug Discovery Foundation
December 10, 2019 08:02 ET | Vaccinex, Inc.
ROCHESTER, N.Y., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel antibody therapies in neurodegenerative diseases and cancer,...
Vaccinex logo
Vaccinex Receives FDA Fast Track Designation for VX15 Antibody for the Treatment of Huntington’s Disease
August 01, 2016 10:05 ET | Vaccinex, Inc.
ROCHESTER, N.Y., Aug. 01, 2016 (GLOBE NEWSWIRE) -- Vaccinex, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for VX15 as a potential...
DiamiR Announces Research Collaboration With Johnson & Johnson Innovation
January 11, 2016 08:02 ET | DiamiR Biosciences Corp.
MONMOUTH JUNCTION, NJ--(Marketwired - January 11, 2016) - DiamiR, LLC, a developer of innovative minimally invasive diagnostic tests, announced today that it has entered into a research...